Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene | Zendy

Lina Aguirre | Zendy; Georgia Colleluori | Zendy; David Robbins | Zendy; Richard I. Dorin | Zendy; Vallabh O. Shah | Zendy; Rui Chen | Zendy; Irum Zeb Jan | Zendy; Clifford Qualls | Zendy; Dennis T. Villareal | Zendy; Reina ArmamentoVillareal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene

Author(s) -

Lina Aguirre,

Georgia Colleluori,

David Robbins,

Richard I. Dorin,

Vallabh O. Shah,

Rui Chen,

Irum Zeb Jan,

Clifford Qualls,

Dennis T. Villareal,

Reina ArmamentoVillareal

Publication year - 2019

Publication title -

endocrine

Language(s) - English

Resource type - Journals

eISSN - 1559-0100

pISSN - 1355-008X

DOI - 10.1007/s12020-019-02008-6

Subject(s) - testosterone (patch) , hematocrit , medicine , bone mineral , endocrinology , lean body mass , genotype , single nucleotide polymorphism , bone density , biology , osteoporosis , gene , genetics , body weight

To evaluate the influence of single nucleotide polymorphisms (SNPs) of CYP19A1 on the response and susceptibility to side effects from testosterone therapy. This is a prospective, single-arm study of men with low-morning serum testosterone (<10.68 nmol/l) administered testosterone cypionate 200 mg intramuscularly every 2 weeks for 18 months.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research